We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bavarian Nordic Research Institute (BAVA) DKK10

Sell:146.70 DKK Buy:146.85 DKK Change: 0.60 DKK (0.41%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:146.70 DKK
Buy:146.85 DKK
Change: 0.60 DKK (0.41%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:146.70 DKK
Buy:146.85 DKK
Change: 0.60 DKK (0.41%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Contact details

Address:
Philip Heymans Alle 3
HELLERUP
2900
Denmark
Telephone:
+ ()
Website:
https://www.bavarian-nordic.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BAVA
ISIN:
DK0015998017
Market cap:
11.46 billion DKK
Shares in issue:
78.05 million
Sector:
Biotechnology
Exchange:
Copenhagen Stock Exchange
Country:
Denmark
Currency:
Danish Krone
Indices:
n/a

Key personnel

  • Paul Chaplin
    President, Chief Executive Officer
  • Anders Pedersen
    Deputy Chairman of the Board
  • Henrik Juuel
    Executive Vice President, Chief Financial Officer
  • Russell Thirsk
    Executive Vice President, Chief Operating Officer
  • Anu Kerns
    Executive Vice President - People and Organization
  • Laurence De Moerlooze
    Executive Vice President, Chief Medical Officer
  • Jean-Christophe May
    Executive Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.